Panobinostat (LBH589)

by Jessica Langholtz
Brand Name:
Generic Name: panobinostat
Code Name: LBH589
Company: Novartis
FDA Clinical Phase: 1

Description:
Panobinostat, which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, panobinostat was highly active as a single agent treatment for several types of cancer, including multiple myeloma, Hodgkin’s lymphoma, acute myeloid leukemia, and prostate cancer. Additional clinical trials are currently underway to examine the efficacy and safety profile of panobinostat.

Clinical Trials:
Currently, there are several open clinical studies involving panobinostat.

Official Web site for panobinostat: http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp

Updated December 3, 2009

Related Articles:

Leave a comment

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.